ArticleInternational journal of pediatric otorhinolaryngology2025
Hearing and neurodevelopmental outcomes among children with congenital cytomegalovirus.
Article in International journal of pediatric otorhinolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveCongenital cytomegalovirus (cCMV) infection is the most common congenital infection and the leading non-genetic cause of sensorineural hearing loss. We assessed demographics, clinical characteristics, hearing and neurodevelopmental outcomes by 6 years of age among U.S. children with possible cCMV. STUDY
designRetrospective cohort design.
settingThe Audiological and Genetic Database (AudGenDB) includes 175,216 pediatric patients who underwent audiology, otology or genetic visits during 2006-2019 in Children's Hospital of Philadelphia, Vanderbilt Children's Hospital, or Boston Children's Hospital.
methodsChildren with possible cCMV were identified by diagnostic codes for cCMV infection and CMV disease up to 6 years of age. We examined clinical signs of cCMV during 0-45 days of birth and neurodevelopmental conditions (including hearing loss) up to 6 years of age. Hearing loss was defined as pure tone average or any frequency threshold ≥25 dB.
resultsA total of 180 (0.1 %) children with possible cCMV were identified; 70 % had diagnosis codes after 45 days of life. The proportions of Black and Hispanic/Latino children comprised a higher proportion in the possible cCMV group compared to the non-cCMV group. Overall, 129 (72 %) children with possible cCMV had diagnoses codes for neurodevelopmental conditions, including hearing loss (56), communication delays (45) and cerebral palsy (22). Hearing loss was diagnosed at a median age of 2 (1-4) years.
conclusionNeurodevelopmental delays were common among children with possible cCMV included in this study. AudGenDB provides access to longitudinal outcomes for a large and diverse cohort that remains helpful in lieu of state-mandated screenings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.